Nodus Oncology, a biotech company based in Edinburgh, announced it has raised £2.4 million from new investor KHAN Technology Transfer Fund I (KHAN-I) as well as Cumulus Oncology.

The company is focused on developing molecules that inhibit novel “third wave” DNA damage response (DDR) targets, a new set of proteins that have recently been discovered and are thought to play important roles in the response to DNA damage.

With this new funding, Nodus, which was found in 2022, will be able to accelerate the development of its PARG programme in collaboration with the Lead Discovery Centre (LDC), continue the development of novel DDR targets and further expand their profile.

“Nodus is focused on developing the next wave of cancer therapeutics in the DDR space, bringing new and effective treatment options to patients,” Ian Waddell, CEO of Nodus Oncology said.

“This funding will allow us to continue to accelerate our development programmes, including our PARG program, and allow us to expand our innovative portfolio. I would like to thank our investors and founders for their ongoing support, and I am looking forward to working together to make a real difference in the fight against cancer.”

Bert Klebl, Managing Director at KHAN0I, and Michael Krebs will be joining Nodus’ Board of Directors as investor representative and observer, respectively.

Recommended

• CodeClan Partners with Eden Scott in Bid to Close Skills Gap
• Biotechnology Network’s Investment in Scots Green Skills Hits £25M
• Digital Xtra Fund Opens 8th Funding Round

“This collaboration illustrates the value-creation opportunity presented by combining Cumulus’ business model, the drug discovery capabilities of the LDC in Dortmund, and the resources of the KHAN-I fund,” said Bert Klebl, “We are looking forward to working with Nodus to accompany it in its growth journey.”

Get all the latest news from DIGIT direct to your inbox

Our newsletter covers the latest technology and IT news from Scotland and beyond, as well as in-depth features and exclusive interviews with leading figures and rising stars.

To subscribe, click here.